AKBA vs. APGE, WVE, SDGR, BLTE, IOVA, IRON, GPCR, INDV, AMPH, and TVTX
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Apogee Therapeutics (APGE), Wave Life Sciences (WVE), Schrödinger (SDGR), Belite Bio (BLTE), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), Structure Therapeutics (GPCR), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.
Akebia Therapeutics vs.
Akebia Therapeutics (NASDAQ:AKBA) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Akebia Therapeutics received 391 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 63.51% of users gave Akebia Therapeutics an outperform vote.
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 4.1% of Akebia Therapeutics shares are owned by insiders. Comparatively, 36.1% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Apogee Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Akebia Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Akebia Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 256.29%. Apogee Therapeutics has a consensus price target of $89.71, suggesting a potential upside of 164.44%. Given Akebia Therapeutics' higher possible upside, equities research analysts plainly believe Akebia Therapeutics is more favorable than Apogee Therapeutics.
In the previous week, Apogee Therapeutics had 7 more articles in the media than Akebia Therapeutics. MarketBeat recorded 11 mentions for Apogee Therapeutics and 4 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.30 beat Apogee Therapeutics' score of 0.17 indicating that Akebia Therapeutics is being referred to more favorably in the media.
Akebia Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.
Akebia Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Akebia Therapeutics beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Akebia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AKBA) was last updated on 2/12/2025 by MarketBeat.com Staff